骨髓转移瘤患者血清乳酸脱氢酶、D-二聚体检测的临床意义  

The Clinical Significance of LDH and D-dimmer Measuring in Patients with Metastatic Carcinoma in Bone Marrow

作　　者：蒋凤莲[1] 施为建[1] 鞠文东[1] 周巧云[1] 

机构地区：[1]广东省中山市博爱医院,528400

出　　处：《实用癌症杂志》2014年第2期137-139,共3页The Practical Journal of Cancer

摘　　要：目的探讨骨髓转移瘤患者血清乳酸脱氢酶(LDH)和D-二聚体检测的临床意义。方法分别测定患者骨髓转移瘤和非骨髓转移瘤患者化疗前后血清LDH和D-二聚体水平。结果骨髓转移组LDH和D-二聚体水平较正常对照组及非骨髓转移组高(P<0.01)。LDH和D-二聚体水平骨髓转移组治疗前后差异无统计学意义(P>0.05),非骨髓转移组治疗前后差异有统计学意义(P<0.01)。结论血清LDH和D-二聚体水平可作为实体瘤患者骨髓浸润与否及疗效判断的辅助指标。Objective To evaluate the clinical significance of the serunl Lactic dehydrogenate ( LDH ) and D-dimme Measuring in patients with Metastatic Carcinoma in Bone Marrow .Methods The level of ( LDH) and D-dimme were tested in the patients without or with Metastatic Carcinoma in Bone Marrow .Results The level of ( LDH) and D-dimme were much higher in patients with Metastatic Carcinoma in Bone Marrow than normal control group and without Metastatic Carcinoma in Bone Mar -row group,there was statistical difference(P<0.01). The level of (LDH)and D-dimme showed no statistical significance in pa-tients without metastatic carcinoma in bone marrow;but it showed statistical significance in patients without metastatic carcinoma in bone marrow.Conclusion The level of LDH and D-dimme can be taken as an auxiliary clinical index to prognosis and effica-cy of patients with metastatic carcinoma in bone marrow .

关 键 词：骨髓转移瘤 乳酸脱氢酶 D-二聚体 

分 类 号：R739.42[医药卫生—肿瘤]